Posts

FDA grants accelerated approval to Inovio’s VOCERYQ for rare HPV-related airway disease

on
On October 30, 2026, the FDA granted accelerated approval to Inovio’s VOCERYQ (formerly INO-3107) to reduce the frequency of surgical papilloma removal in adults with recurrent respiratory papillomatosis (RRP). RRP is a rare, chronic disease usually associated with HPV-6 or HPV-11. It causes wart-like growths in the airways that can return after surgery and may affect speaking or breathing. VOCERYQ is a plasmid DNA-based immunotherapy designed to prompt an immune response against HPV-6 and HPV-11. It is the first FDA-approved plasmid DNA-based immunotherapy, according to the FDA and Inovio. The approval relied on the RRP-001 study. In the FDA’s efficacy group of 26 patients, 7 (27%) went 12 months without another surgical excision. The approval is conditional under the FDA’s accelerated-approval pathway: Inovio must conduct a confirmatory study to verify clinical benefit. Inovio said it expected ordering and shipping to begin in about 60 days, with a broader launch planned fo...

Rare kidney disease: closing the gap between discovery and care

on

ETX101 shows promising early signals in Dravet syndrome

on

Sanofi rules out major restructuring as it prepares for Dupixent’s patent loss

on

FDA approves camizestrant combination for ESR1-mutated advanced breast cancer

on

Recent Alzheimer’s developments across France, Germany, Italy and Spain

on

Actio’s remaining drug pipeline moves to Setara after Jazz buyout

on

Lilly raises 2026 outlook as GLP-1 demand and Medicare Bridge access boost sales

on

AstraZeneca targets $1.5B in annual savings to reinvest in its pipeline

on

Sanofi weighs selective “moonshot” deals as it plans for the Dupixent patent cliff

on

Dren Bio raises $350 million to advance rare blood cancer drug

on

Flagship combines three biotech platforms to launch AI drug-discovery company Etcelera

on

Aspen raises $141M and Bambusa brings in $169M in biotech IPOs

on